Drugs in Context (Nov 2023)

Sleep-related breathing disorder (central sleep apnoea) improved coincidentally by medical therapy with fumarates (dimethyl fumarate)

  • Abdulmajeed M Albadi,
  • Mana M Alshahrani,
  • Riyad O Allehebi

DOI
https://doi.org/10.7573/dic.2023-6-3
Journal volume & issue
Vol. 12
pp. 1 – 5

Abstract

Read online

Central sleep apnoea (CSA) is a sleep disorder characterized by the repeated cessation or reduction of both airflow and ventilatory effort when sleeping. Individuals with central breathing disorders have difficulty in receiving appropriate medical treatment. In this article, we describe a case study of a 31-year-old woman known to have multiple sclerosis and concomitant severe CSA. She received the medication dimethyl fumarate for the treatment of multiple sclerosis, and her CSA significantly improved to mild CSA after the treatment.

Keywords